Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
GHRS | US
-0.30
-2.49%
Healthcare
Biotechnology
31/03/2024
05/07/2024
11.75
12.09
12.20
11.62
GH Research PLC a clinical-stage biopharmaceutical company engages in developing various therapies to treat psychiatric and neurological disorders. The company develops 5-Methoxy-NN-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001 an inhalable mebufotenin product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002 an intravenous mebufotenin product candidate; and GH003 an intranasal mebufotenin product candidate which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin Ireland.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
40.5%1 month
72.1%3 months
66.7%6 months
68.8%-
-
2.66
0.00
0.00
-11.97
-
-
-42.01M
611.33M
611.33M
-
-
-
-
-14.31
22.39
8.94
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.04
Range1M
3.81
Range3M
4.69
Rel. volume
0.33
Price X volume
218.90K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
UroGen Pharma Ltd | URGN | Biotechnology | 15.88 | 653.15M | 5.80% | n/a | -246.69% |
Sage Therapeutics Inc | SAGE | Biotechnology | 10.78 | 648.76M | 1.51% | n/a | 0.47% |
Pliant Therapeutics Inc. | PLRX | Biotechnology | 10.52 | 634.63M | -0.57% | n/a | 12.50% |
Humacyte Inc | HUMA | Biotechnology | 5.27 | 627.57M | -7.05% | n/a | 71.00% |
Scholar Rock Holding Corporation | SRRK | Biotechnology | 7.74 | 617.30M | -0.39% | n/a | 32.90% |
Savara Inc | SVRA | Biotechnology | 4.43 | 612.18M | 2.31% | n/a | 21.80% |
Lexicon Pharmaceuticals Inc | LXRX | Biotechnology | 1.67 | 603.69M | 0.60% | n/a | 36.78% |
PHATHOM PHARMACEUTICALS INC. | PHAT | Biotechnology | 10.3 | 602.91M | 0.49% | n/a | -315.85% |
Travere Therapeutics Inc. | TVTX | Biotechnology | 7.89 | 600.66M | -0.63% | n/a | 545.44% |
Mineralys Therapeutics Inc. | MLYS | Biotechnology | 12.43 | 597.61M | 2.30% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Malibu Boats Inc | MBUU | Recreational Vehicles | 32.65 | 667.35M | -2.74% | n/a | 4.21% |
Ennis Inc | EBF | Building Products & Equipment | 21.25 | 552.16M | -0.75% | 13.68 | 1.15% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 4.48 | 428.47M | -2.40% | n/a | 138.85% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 25.77 | 412.92M | -1.68% | n/a | 322.60% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.74 | 369.15M | -2.49% | 14.12 | 86.68% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.36 | 324.63M | -2.40% | 10.10 | 0.00% |
Latham Group Inc. | SWIM | Building Products & Equipment | 2.74 | 316.67M | -3.52% | 75.75 | 80.81% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.55 | 298.02M | -0.34% | 8.24 | 25.57% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 26.52 | 294.97M | -4.29% | 17.47 | -562.47% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 12.93 | 209.56M | -2.78% | 8.94 | 15.44% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -11.97 | -2.43 | Cheaper |
Ent. to Revenue | - | 4,101.76 | - |
PE Ratio | - | 41.26 | - |
Price to Book | 2.66 | 22.34 | Cheaper |
Dividend Yield | - | 2.39 | - |
Std. Deviation (3M) | 66.71 | 76.52 | Par |
Debt to Equity | 0.00 | 0.51 | Cheaper |
Debt to Assets | 0.00 | 0.24 | Cheaper |
Market Cap | 611.33M | 3.77B | Emerging |